Abstract
Intensive care unit (ICU) sedation with sevoflurane is associated with nephrogenic diabetes insipidus. Given that isoflurane is now licenced (in Europe) for ICU sedation and has Investigational New Drug status in the USA, evidence indicates that clinicians should stop using sevoflurane in this indication except in the context of clinical trials.
| Original language | English |
|---|---|
| Pages (from-to) | 7-10 |
| Number of pages | 4 |
| Journal | British Journal of Anaesthesia |
| Volume | 129 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jul 2022 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine
Keywords
- acute kidney injury
- diabetes insipidus
- isoflurane
- nephrotoxicity
- sedation
- sevoflurane
Fingerprint
Dive into the research topics of 'Avoiding kidney damage in ICU sedation with sevoflurane: use isoflurane instead'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver